King Of Prussia

CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment

Firms to provide enhanced solutions to life sciences organizations globally

Patients 'lost' from a clinical trial result in study delays, increased patient recruitment costs and compromised study data. L2FU provides critical solutions.

MediciGlobal team members lead the way in 'Extreme Charity'

First release designed for consumer goods companies includes business-process and pre-configured software components to accelerate implementations and optimize ROI in enterprise technology.

KING OF PRUSSIA, Pennsylvania, May 31, 2011 - CSL Behring announced today that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.

MORE..

KING OF PRUSSIA, Pennsylvania, September 15, 2010 - Tunnell Consulting, Inc.

MORE..

KING OF PRUSSIA, Pennsylvania, July 22, 2010 - Recovering unnecessarily lost patient information is now a viable reality.

MORE..

KING OF PRUSSIA, Pennsylvania, and LONDON, June 30, 2010 - Participating in 'extreme charity' events aptly describes the commitment of MediciGlobal's employees to raising money for noteworthy causes.

MORE..

Older News

KING OF PRUSSIA, Pennsylvania, January 14 - Linx/AS LLC (www.linxas.com), a consulting and software development firm specializing in product lifecycle management (PLM) and regulatory & compliance, has announced the release of its Best Practices for SAP Recipe Management -- industry-targeted solutions that include project analysis and planning models; industry-standard business process flows, configuration templates for the SAP Recipe Management module; and a suite of technical accelerators, such as role-based web GUI packages and mass data management tools.

MORE..